MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics
Frontiers in Immunology · 05.05.2026 · 17
DOI: 10.3389/fimmu.2026.1789537 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Frontiers in Immunology, online erschienen am 05.05.2026. Verfasst von Rocío Maseda und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, La Paz University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Mesenchymal Stem Cell Transplantation, Chemokine CCL2, CD40 Ligand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Carlos III de Madrid.
Abstract (Originalsprache)
Background
Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic COL7A1 mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory control remains a major unmet need. While systemic administration of mesenchymal stromal cells (MSC) from various sources has proven safe with transient benefits yet only one recent placebo-controlled study in RDEB. Consistent type VII collagen (C7) deposition is lacking, and therapeutic mechanisms and predictive biomarkers remain undefined. The MesenSistem-EB trial evaluated for the first time the use of haploidentical BM-MSC and extensively explored their anti-inflammatory potential as a monotherapy in RDEB.
Methods
Phase I/II, single-center, open-label trial, in which nine children with severe RDEB were recruited and eight completed the study after three intravenous infusions of haploidentical BM-MSC (2–3×10 6 cells/kg) at 21-day intervals. Safety, clinical and patient-reported outcomes, systemic inflammatory mediators and peripheral blood immune profiles were assessed over 12 months.
Results
MSC therapy was well-tolerated without serious adverse events. Long-term pruritus, sleep and fatigue were globally reduced. In 7/8 patients at least one key domain significantly improved (disease severity, pruritus, or inflammation) with five classified as good responders. Global median CRP and fibrinogen levels remained stable throughout the study period. Responses correlated with sCD40L and MCP1 dynamics. Flow cytometry revealed altered circulating myeloid and lymphoid compartments at baseline. Post-infusion, immune cell subset changes did not consistently distinguish responders while typically including increased CLA expression on monocytes, partial recovery of memory CD8 + T cells and disappearance of an aberrant granulocyte population, potentially linked to immature myeloid mobilization driven by chronic inflammation. Haploidentical MSC did not consistently confer durable engraftment or sustained C7 deposition.
Conclusions
BM-MSC is a safe and potentially effective anti-inflammatory intervention that mitigates the expected escalation of systemic inflammatory markers during a critical phase of RDEB progression. MCP1 and sCD40L modulation, with both potentially serving as predictive biomarkers. MSC appear to exert both shared and patient-specific immunomodulatory effects depending on baseline inflammatory cues. Findings provide insights into individual variability, underlying mechanisms and potential therapeutic responsiveness, supporting their use also as a complementary strategy. Clinical trial registration ClinicalTrials.gov , identifier NCT04153630.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, La Paz University Hospital, Madrid, Spain.
- U714-CIBERER (Centro de Investigación Biomédica en Red de Enfermedades Raras), Madrid, Madrid, Spain.
- Department of Bioengineering, Universidad Carlos III de Madrid (UC3M), Madrid, Spain.
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
- Spanish Network of Advanced Therapies by TERAV-ISCIII, Madrid, Spain.
- Cell Biology Department, Faculty of Medicine, Complutense University, Madrid, Spain.
Förderung
- Universidad Carlos III de Madrid
Zitieren
APA
Maseda, R., Arriba, M. C., Martínez-Santamaría, L., Jiménez, E., Herráiz-Gil, S., Illera, N., Quintana-Castanedo, L., García, M., Suárez-Sancho, S., Yáñez, R., Pérez-Conde, I., Carretero, M., Martínez-Queipo, M., de Paz, R., León, C., Jiménez-Yuste, V., Borobia, A. M., Vicente, Á., Lwin, S. M., …, & Escámez, M. J. (2026). MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1789537
Vancouver
Maseda R, Arriba MC, Martínez-Santamaría L, Jiménez E, Herráiz-Gil S, Illera N, et al. MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1789537
BibTeX
@article{Maseda2026,
author = {Maseda, Rocío and Arriba, María Carmen and Martínez-Santamaría, Lucía and Jiménez, Eva and Herráiz-Gil, Sara and Illera, Nuria and Quintana-Castanedo, Lucía and García, Marta and Suárez-Sancho, Susana and Yáñez, Rosa and Pérez-Conde, Isabel and Carretero, Marta and Martínez-Queipo, Magdalena and de Paz, Raquel and León, Carlos and Jiménez-Yuste, Víctor and Borobia, Alberto M and Vicente, Ángeles and Lwin, Su M and McGrath, John A and Fernández-Santos, María Eugenia and Butta, Nora and Sacedón, Rosa and Del Río, Marcela and de Lucas, Raúl and Escámez, María José},
title = {MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1789537}
}
EUVIMED